Complement-dependent lymphocytotoxicity crossmatches (n=217) between 47 deceased donors and 150 potential renal recipients were retrospectively studied. A negative cross match was reported in 48 (22.1%), doubtful positive in 126 (58.1%), weakly positive in 32 (14.7%) and positive in 11 (5.1%). No autoantibodies were detected. Renal transplantation was performed in 35.5% of the potential recipients. There was no incidence of hyperacute rejection. The graft survival rate was 88% at 15 months of follow up. The study concludes that a negative pretransplant lympocytotoxicity crossmatch using the basic National Institute of Health technique eliminates hyperacute rejection, but carries drawbacks, which require modification and supplementation with...
The aim of the present study was to describe the association of positive flow cross match (FXM) and ...
In order to select recipients without donor-specific anti-HLA antibodies, the complement-dependent c...
Complement-dependent lymphocytotoxicity cross match (CDC-XM) is the ultimate test of donor/recipient...
Complement-dependent lymphocytotoxicity crossmatches (n=217) between 47 deceased donors and 150 pote...
A false-positive complement-dependent cytotoxicity cross-match (CDC XM) has a negative impact in don...
Transplant recipients are always at a risk of developing anti-human leukocyte antigen (HLA) antibodi...
Recently, Luminex-crossmatch (LumXm) was introduced. The aim of this study was to evaluate clinical ...
Allografting patients with human leukocyte antigens (HLA) which are recognized by preformed antibodi...
No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically ...
Pretransplantation crossmatching is an integral part of kidney transplantation. Flow cytometric cros...
Cytotoxic flow cytometric crossmatch (cFCXM), identified by detecting complement-mediated cytotoxic ...
BACKGROUND: This study evaluated the prognostic impact of pretransplant donor-specific anti-human le...
Background. Sensitized patients (pts) may develop acute antibody-mediated rejection (AMR) due to pre...
Crossmatching is essential prior to kidney transplantation to confirm compatibility between the dono...
Background. Human leukocyte antigen (HLA) antibody-incompatible renal transplantation has been incre...
The aim of the present study was to describe the association of positive flow cross match (FXM) and ...
In order to select recipients without donor-specific anti-HLA antibodies, the complement-dependent c...
Complement-dependent lymphocytotoxicity cross match (CDC-XM) is the ultimate test of donor/recipient...
Complement-dependent lymphocytotoxicity crossmatches (n=217) between 47 deceased donors and 150 pote...
A false-positive complement-dependent cytotoxicity cross-match (CDC XM) has a negative impact in don...
Transplant recipients are always at a risk of developing anti-human leukocyte antigen (HLA) antibodi...
Recently, Luminex-crossmatch (LumXm) was introduced. The aim of this study was to evaluate clinical ...
Allografting patients with human leukocyte antigens (HLA) which are recognized by preformed antibodi...
No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically ...
Pretransplantation crossmatching is an integral part of kidney transplantation. Flow cytometric cros...
Cytotoxic flow cytometric crossmatch (cFCXM), identified by detecting complement-mediated cytotoxic ...
BACKGROUND: This study evaluated the prognostic impact of pretransplant donor-specific anti-human le...
Background. Sensitized patients (pts) may develop acute antibody-mediated rejection (AMR) due to pre...
Crossmatching is essential prior to kidney transplantation to confirm compatibility between the dono...
Background. Human leukocyte antigen (HLA) antibody-incompatible renal transplantation has been incre...
The aim of the present study was to describe the association of positive flow cross match (FXM) and ...
In order to select recipients without donor-specific anti-HLA antibodies, the complement-dependent c...
Complement-dependent lymphocytotoxicity cross match (CDC-XM) is the ultimate test of donor/recipient...